CD4 and Hyperglycemia: In a recent clinical trial on the immunogenicity of mRNA- or adenovirus vector-based COVID-19 vaccines following two-dose administration in T2DM patients with glycemic monitoring (using HbA1c values), the results indicated that hyperglycemia at time of vaccination worsened the antigen-specific CD4 cell activity and antibody production whereas post-vaccination glycemic control could reverse the situation and improve the immune response (51).